Cancer Letters · 2020 · 28 citations · 20 references
MedicineOncologyPharmacologyApoptosisMolecular OncologySignal TransductionApoptosis EvasionApoptosis ResistanceCell Cycle PharmacologyCell-cycle DysregulationMitotic InhibitorsTherapeutic ResistanceAnticancer Drug ResistanceBreast Cancer Resistance MechanismsCancer Cell Proliferation InhibitionCaspase-mediated ApoptosisProtein Kinase InhibitorsResistance To Mitotic InhibitorsTherapeutic Resistance MechanismsTriple-negative Breast Cancer Therapy
The inhibition of bromo- and extraterminal domains (BET) has shown an anti-proliferative effect in triple negative breast cancer (TNBC). In this article we explore mechanisms of resistance to BET inhibitors (BETi) in TNBC, with the aim of identifying novel ways to overcome such resistance. Two cellular models of acquired resistance to the BET inhibitor JQ1 were generated using a pulsed treatment strategy. MTT, colony formation, and cytometry assays revealed that BETi-resistant cells were particularly sensitive to PLK1 inhibition. Targeting of the latter reduced cell proliferation, especially in resistant cultures. Quantitative PCR analysis of a panel of mitotic kinases uncovered an increased expression of AURKA, TTK, and PLK1, confirmed by Western blot. Only pharmacological inhibition of PLK1 showed anti-proliferative activity on resistant cells, provoking G2/M arrest, increasing expression levels of cyclin B, pH3 and phosphorylation of Bcl-2 proteins, changes that were accompanied by induction of caspase-dependent apoptosis. JQ1-resistant cells orthotopically xenografted into the mammary fat pad of mice led to tumours that retained JQ1-resistance. Administration of the PLK1 inhibitor volasertib resulted in tumour regression. These findings open avenues to explore the future use of PLK1 inhibitors in the clinical setting of BETi-resistant patients.
20
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu, Charles Y. Lin, Housheng Hansen He et al. · Nature · 2016 · 629 citations · Full text
Medicine, Oncology, Pharmacology +14
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong, Omer Gilan, Enid Y.N. Lam et al. · Nature · 2015 · 548 citations · Full text
Medicine, Cancer Biology, Oncology +14
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert, Mareike Roth, Tobias Neumann et al. · Nature · 2015 · 522 citations · Full text